Oxford Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Oxford Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20,269	Closed	-$187K	–	1501
2019 Q4	$187K	Buy	+20,269	New	+$144K	0.01%	1563
2018 Q4	–	Sell	-177,372	Closed	-$2.62M	–	2197
2018 Q3	$2.62M	Buy	177,372 +47,963	+37%	+$755K	0.05%	515
2018 Q2	$2.2M	Buy	129,409 +42,581	+49%	+$827K	0.04%	610
2018 Q1	$1.99M	Sell	86,828 -112,053	-56%	-$2.49M	0.04%	583
2017 Q4	$5.2M	Buy	+198,881	New	+$4M	0.11%	218
2017 Q3	–	Sell	-19,711	Closed	-$275K	–	1761
2017 Q2	$275K	Buy	19,711 +5,835	+42%	+$86K	0.01%	1281
2017 Q1	$237K	Buy	+13,876	New	+$166K	0.01%	1273
2016 Q4	–	Sell	-49,104	Closed	-$496K	–	893
2016 Q3	$496K	Sell	49,104 -146,280	-75%	-$1.6M	0.02%	618
2016 Q2	$2.19M	Sell	195,384 -13,510	-6%	-$172K	0.07%	350
2016 Q1	$2.85M	Sell	208,894 -105,044	-33%	-$1.51M	0.08%	293
2015 Q4	$5.99M	Buy	+313,938	New	+$6.82M	0.14%	146

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oxford Asset Management's CNCE Position: Q1 2020 in Review

Oxford Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2020, closing a stake of 20,269 shares — an estimated $187K sold.

Oxford Asset Management first reported a position in CNCE in Q4 2015 and held it in 11 quarters. The position peaked at $5.99M in Q4 2015. 79 funds tracked by Wall St. Rank hold CNCE as of Q1 2020.

Oxford Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 20,269 Concert Pharmaceuticals, Inc. shares in Q1 2020, an estimated $187K.
Oxford Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 11 quarters.
Oxford Asset Management's Concert Pharmaceuticals, Inc. position peaked at $5.99M in Q4 2015.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.